Summary of the technology
A fraction of compounds obtained from Ganoderma lucidum has been described. This fraction is active on murine lymphoma DA-1 cells and human leukemia NB4 cells. This fraction induced DNA fragmentation, changes in cell membrane and cell death.
The innovation lies on the antitumor activity, the source of such compounds (the mushroom Ganoderma lucidum grown in stablished conditions developed in our lab).
Description of the technology
A multidisciplinary research group at the University of Alcalá (Biochemical and Plant Biology Department) has isolated a chromatographic fraction from cultured fruiting bodies of Ganoderma lucidum and its analysis by HPLC-Chromatography Mass Spectrometry. This fraction can be useful for the development of new pharmaceutical formulations in the treatment of tumour activity of cancer cells, since cytotoxic activity was detected and apoptotic cells in murine lymphoma and human leukemia. The group looks for companies from the sectors of health sciences and more specifically pharmaceuticals, for technical cooperation agreements or joint-venture.
This invention belongs to the area of obtaining natural products with low toxicity traditionally used in Oriental Medicine based on a sample preparation of compounds of Ganoderma lucidum that can be used for anticancer drug such as human leukemia, lymphoma, etc ... The technique consists in the procedure for obtaining a fraction of a Semipurified Active of cultivated fruiting bodies of Ganoderma lucidum (FSAGL) by extraction in 10% methanol. To learn the chemical elements that make up the FSAGL, i.e. to determine the elemental composition of the sample in both qualitative and quantitative elemental analysis was performed. The results of the analysis of the elements that compose the body FSAGL successful show consists mainly of carbon (about 50%) and oxygen (32.3%) and to a lesser extent, hydrogen and nitrogen. The extract of Ganoderma lucidum is silica-gel column chromatography using mobile phase of butanol: acetic acid: water (3:1:1). The active fraction has a Rf of 0.7. This fraction was analyzed by HPLC-Mass. The active fraction is capable of inducing cell death in murine lymphoma and leukemic human tumour cells by promoting programmed cell death. It also causes changes in the levels of expression of apoptotic factors p53, Bcl2, Bax and the dephosphorylated and phosphorylated forms of intracellular kinases such as Erk and Akt.
Main advantages of its use
- The invention could be useful in developing new pharmaceutical formulae for treatment of antitumor activity of cancer and leukemia cells. The growth of Ganoderma lucidum and the process of isolation of the active fraction do not have big costs.
- Pharmaceuticals companies